FDA Postpones Foreign Inspections Due To Coronavirus Outbreak
Critical Inspections Will Be Considered Case-By-Case
The US FDA is postponing “most foreign inspections” through April as a result of the coronavirus outbreak, because it will temporarily not be able to physically inspect foreign produced FDA-regulated products or manufacturers. However, inspections outside the US deemed as critical “will still be considered on a case-by-case basis.”
You may also be interested in...
Viatris and partner Biocon have seen FDA action on their application for a bevacizumab biosimilar rival to Avastin delayed by the need for a facility inspection, the timing of which is uncertain due to coronavirus-related restrictions.
Specific guidance for ANDA sponsors on bioequivalence studies during the COVID-19 pandemic has been published by the US FDA.
After postponing foreign inspections, the US FDA has further decided to scale back domestic inspections due to the coronavirus outbreak.